Cancer Treatment Centers of America: A Model Approach

Cancer Treatment Centers of America (CTCA) is a for-profit hospital offering several locations throughout the United States. The treatment centers are located in the metropolitan areas of Atlanta, Chicago, Philadelphia, Phoenix and Tulsa.

CTCA utilizes an integrative approach in treating all forms of cancer. Integrative care can best be defined as conventional treatments merged with supportive therapies. The cancer treatment itself attacks the cancer cells, while the supportive therapies aid in combating anxiety, stress, headaches, loss of appetite, fatigue, insomnia and other symptoms. Personalized care is a component of the integrative care model. CTCA considers each cancer as distinctive as the person battling it. Because CTCA only treats cancer, it can ascertain the best course of treatment based on the individual’s particular and unique needs.

One of the benefits to obtaining cancer treatment at CTCA is that all care is provided under one roof. Patients can relax and focus without the stress of jumping from one medical facility to another. From the start, a care manager is assigned to each patient. The care manager will advocate for the patient and help him or her navigate the evaluation and treatment process. Onsite labs at each treatment center hasten test results and diminish appointment wait times.

CTCA champions patient-centered care. One way CTCA accomplishes this is to provide strong support to the patient’s caregiver(s). When a loved one is stricken with cancer, it is essential that caregivers be kept informed of treatment options, side-effect management and the patient’s overall health. It is a stressful time for all involved, and CTCA has a program in place for scheduling appointments, making travel arrangements and record keeping. CTCA also offers patient-to-patient networking. Patients and caregivers can speak directly with other patients – either by email or phone – for advice or encouragement as they tackle what can be an overwhelming diagnosis.

In addition to cutting-edge cancer treatment, CTCA is a frontrunner in marketing initiatives. WebMD and CTCA collaborate to provide visitors in-depth information on WebMD’s site regarding the latest treatments and developments in cancer care.

Cancer Treatment Centers of America was founded in 1988 by Robert Stevenson, an investment banker. Mr. Stevenson, not satisfied with the care his mother received before dying of cancer, brought about the CTCA Mother Standard™ of care. The CTCA website describes this model as, “a unique, patient-centered model of cancer care originated out of respect for Mr. Stephenson’s departed mother, in whose memory CTCA was founded, and in whose memory he, his family and all of CTCA have pledged to change the face of this terrible disease, NOW!”

Details Cancer Care:  Facebook.com/cancercenter/

Clay Siegall’s role in Cancer Treatment

National Cancer Institute states that about 40 percent of women and men in the U.S will at one point of their life be diagnosed with some form of cancer. Over 600,000 people lost their cancer battles in U.S alone. Given these shocking statistics, it is obvious to feel like there is little that is being done about this terrible disease, but that is not the case. Biotech firms like the Seattle genetics are pushing the cancer treatment and research boundaries with men like Clay Siegall at their top. Their commitment enables them to make significant progress in the field.

Dr.Clay Siegall is the CEO and founder of Seattle Genetics, a biotech firm based in Seattle that specializes in targeted therapy drugs development for the types of diseases that have not seen any substantial mortality improvements in decades. He holds a B.S in Zoology from the University of Maryland and a genetics Ph. D. from Gorge Washington University.

Since he established the Seattle Genetic back in 1998, Dr. Siegall has led his firm to great heights in the targeted therapy industry through the development of the first FDA-approved conjugate antibody drug, which currently has multiple approved indications. Clay has also developed a robust pipeline of more than 20 drugs and some strategic partnerships with manufacturers of drugs including Genentech, Bayer, Pfizer, and others.

Seattle Genetics under the leadership of Dr. Siegall has grown from a small startup with just a few researchers to a great power player in the research space of cancer. Mr. Siegall has big plans for the future of the company. With the expanding list of the drugs in its development pipeline and an ever increasing number of prospective indications for the existing drug portfolio of the company, the firm is in an excellent position to move with authority into the 21st-century industry in drug development.

Dr. Siegall also worked with the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. Clay is one of the Boards of Trustees of Ultrageny Pharmaceutical, Washington Round table, and Alder Bio Pharmaceuticals. Dr. Siegall has been a recipient of several awards which includes University of Maryland Alumnus of the year for Math, Natural Sciences and Computer in 2013, and the Pacific North Ernst and Young Entrepreneur of the year in 2012. He has written seventy publications and holds 15 patents.